Idexx Laboratories IDXX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 62.1%+0.8pp | 61.8%+0.8pp | 61.7%+1.0pp | 61.5%+1.1pp | 61.3%+1.1pp | |
| Operating margin | 31.6%+2.5pp | 31.6%+2.7pp | 31.3%+2.4pp | 31.1%+2.5pp | 29.1%-0.8pp | |
| Net margin | 24.6%+1.9pp | 24.6%+1.8pp | 24.7%+2.1pp | 24.4%+2.1pp | 22.8%-0.5pp | |
| EBITDA margin | 35%+2.4pp | 35%+2.7pp | 34.7%+2.5pp | 34.5%+2.7pp | 32.6%-0.5pp | |
| Free cash flow margin | 24.4%+2.8pp | 24.6%+3.8pp | 23.1%+2.5pp | 19.4%-2.7pp | 21.6%+0.2pp | |
| Returns | ||||||
| Return on equity | 72.9%+13.6pp | 66.2%+8.5pp | 64.6%+5.2pp | 64.9%+1.6pp | 59.3%-12.6pp | |
| Return on assets | 33.2%+5.9pp | 31.9%+4.8pp | 30.5%+3.6pp | 29.2%+2.3pp | 27.3%-0.9pp | |
| Return on invested capital | 56.9%+11.4pp | 53.8%+7.4pp | 51.8%+6.8pp | 51%+6.2pp | 45.4%-3.8pp | |
| Efficiency | ||||||
| Asset turnover | 1.3×+0.2× | 1.3×+0.1× | 1.2×0.0× | 1.2×0.0× | 1.2×0.0× | |
| Inventory turnover | 4.3×+0.5× | 4.3×+0.3× | 4.1×+0.2× | 4×+0.2× | 3.9×+0.1× | |
| Liquidity | ||||||
| Current ratio | 1.1×0.0× | 1.2×-0.1× | 1.2×-0.2× | 1.1×-0.3× | 1.2×-0.4× | |
| Quick ratio | 0.8×0.0× | 0.9×-0.1× | 0.9×-0.2× | 0.8×-0.2× | 0.8×-0.4× | |
| Cash ratio | 0.2×0.0× | 0.2×-0.1× | 0.2×-0.1× | 0.1×-0.2× | 0.1×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×-0.1× | 0.4×-0.1× | 0.4×0.0× | 0.5×-0.1× | 0.5×0.0× | |
| Debt-to-assets | 0.2×-0.1× | 0.2×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Net debt / EBITDA | 0.2×-0.2× | 0.3×-0.1× | 0.3×0.0× | 0.4×0.0× | 0.4×+0.1× | |
| Interest coverage | 36.1×-0.9× | 35×-1.2× | 35.2×+1.4× | 36.7×+4.8× | 37×+6.3× | |
| Per Share | ||||||
| Book value per share | $19.41+9.8% | $19.81+3.4% | $19.35-0.7% | $18.01-4.9% | $17.68-5.4% | |
| Valuation | ||||||
| Market capitalization | $44.63B+31.1% | $54.02B+59.6% | $51.11B+22.4% | $42.66B+5.4% | $34.03B-24.1% | |
| Enterprise value | $45B+30.0% | $54.42B+58.6% | $51.56B+22.2% | $43.16B+5.5% | $34.61B-23.6% | |
| Price / earnings | 40.7×+2.7× | 51×+12.9× | 49.7×+1.6× | 43.3×-4.6× | 38×-13.7× | |
| Price / sales | 10×+1.4× | 12.6×+3.9× | 12.3×+1.4× | 10.6×-0.1× | 8.7×-3.4× | |
| Price / book | 28.7×+5.2× | 33.7×+12.4× | 32.7×+6.9× | 29.2×+3.6× | 23.5×-5.1× | |
| EV / EBITDA | 28.9×+1.9× | 36.2×+8.9× | 35.7×+1.6× | 31×-3.0× | 27×-9.7× | |
| EV / sales | 10.1×+1.3× | 12.6×+3.8× | 12.4×+1.4× | 10.7×-0.1× | 8.8×-3.4× | |
| Free cash flow yield | 2.4%-0.1pp | 2%-0.4pp | 1.9%0.0pp | 1.8%-0.2pp | 2.5%+0.7pp | |
| Earnings yield | 2.5%-0.2pp | 2%-0.7pp | 2%-0.1pp | 2.3%+0.2pp | 2.6%+0.7pp | |
| PEG ratio | 1.8×-9.8× | 2.6×-4.9× | 2.7×-6.4× | 2.6×-4.4× | 11.6×+9.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Idexx Laboratories's profit margins?
- Idexx Laboratories (IDXX) runs a 62.1% gross margin and a 31.6% operating margin, with a 24.6% net margin.
- Where do Idexx Laboratories's ratios come from?
- Every ratio is computed from Idexx Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
